GoodRx Holdings, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data GoodRx Holdings, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	250	388	551	745	767	750	792	797
Cost of revenue	6.04	14	29.6	46.7	65.1	66.9	48.2	57.6
Gross profit	243	374	521	699	701	683	744	739
Research and development	43.9	29.3	61.8	126	143	136	124	121
Selling and marketing	104	177	255	370	358	341	367	332
General and administrative	8.36	14.7	461	155	145	126	118	114
Operating income	77.3	140	-276	13.4	1.74	-27	65.8	87.5
Interest expense	22.2	49.6	27.9	23.6	34.2	56.7	52.9	42.6
Interest income	0.15	0.72	0.16	0.06	9.27	32.2	23.3	10.9
Other non-operating income	-24.9	-56.7	-27.7	-23.6	-25	-28.6	-34.4	-31
Pre-tax income	52.3	83	-303	-10.2	-23.2	-55.6	31.5	56.5
Income tax	8.56	16.9	-9.83	15.1	9.6	-46.7	15.1	26.1
Net income	43.8	66	-294	-25.3	-32.8	-8.87	16.4	30.4
EBITDA	87.1	153	-257	47.9	55.9	80.7	135	173
EPS, basic	0.12	0.19	-1.07	-0.06	-0.08	-0.02	0.04	0.09
EPS, diluted	0.12	0.18	-1.07	-0.06	-0.08	-0.02	0.04	0.09
Shares, basic (weighted)	112	227	275	410	413	410	386	356
Shares, diluted (weighted)	118	231	275	410	413	410	392	357

Balance sheet

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	34.6	26.1	969	941	757	672	448	262
Receivables		48.1	68.7	118	117	144	146	236
Other current assets		12.4	46	29.6	3.1	56.9	42	47.2
Total current assets		86.6	1,086	1,089	920	873	659	643
Property, plant and equipment		1.86	23.1	21.6	19.8	15.9	12.7	12.3
Lease right-of-use assets		32.3	27.7	20.2	8.9	29.9	27.8	28.8
Goodwill	220	236	261	330	412	411	411	430
Intangible assets		21.3	36.9	88.8	120	60.9	52.1	64.1
Other non-current assets		1.16	2.03	6.01	27.2	37.8	23.5	29.1
Total assets		387	1,470	1,608	1,605	1,589	1,388	1,404
Accounts payable		7.85	10.3	17.5	17.7	36.3	14.1	19.4
Deferred revenue		3.45	6.85	6.87	7.88	7.11	6.04	6.71
Short-term debt		7.03	7.03	7.03	7.03	8.79	5	5
Total current liabilities		33.4	59.6	81.1	76.3	123	124	246
Long-term debt		664	660	656	652	648	487	483
Lease liabilities		37.1	33.5	33.6	54.1	48.4	46	49.8
Other non-current liabilities		2.97	5.85	5.38	7.56	8.18	6.76	8.74
Total liabilities		737	759	776	790	827	663	788
Total debt		671	681	674	667	656	500	495
Paid-in capital		8.79	2,102	2,247	2,263	2,219	2,166	2,027
Retained earnings		-1,097	-1,390	-1,416	-1,449	-1,457	-1,441	-1,411
Shareholders' equity	-1,162	-1,088	711	832	815	762	725	616
Total equity	-1,162	-1,088	711	832	815	762	725	616
Total liabilities and equity		387	1,470	1,608	1,605	1,589	1,388	1,404

Cash flow statement

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	43.8	66	-294	-25.3	-32.8	-8.87	16.4	30.4
Depreciation and amortization	9.81	13.6	18.4	34.5	54.2	108	69.5	85.2
Stock-based compensation	1.76	3.75	397	160	120	105	99	76.6
Deferred income tax	-2.43	-5.67	-10.9	12.9	-0.5	-65.6	-11.9	20.1
Change in receivables	-12.8	-14.5	-16.1	-43.9	1.38	-26.5	-2.33	-88
Change in payables	0.67	0.52	2.15	4.21	-0.87	12	-15.8	4.1
Cash from operations	45.3	83.3	131	179	147	138	184	168
Capital expenditures	-0.8	-1.43	-20.6	-4.57	-3.97	-1.04	-1.24	-3.52
Acquisitions		-31.3	-55.8	-140	-157	0	0	-43.4
Cash from investing	-3.46	-37.1	-91.6	-179	-210	-55.8	-70.3	-120
Debt issued	902	155	28	0	0	0	472	0
Debt repaid	-295	-212	-35	-7.03	-7.03	-5.27	-639	-5
Stock issued	3.35	1.62	0	0	9.16	5.94	19	0.06
Share buybacks			0	0	-102	-104	-159	-216
Dividends paid	-1,346
Cash from financing	-24.7	-54.8	906	-30.5	-120	-167	-337	-234
Net change in cash	17.1	-8.55	946	-30.5	-184	-84.9	-224	-187
Free cash flow	44.4	81.9	111	174	143	137	183	164
Interest paid	18.7	48.4	24.5	20.2	30.7	48.8	55.1	40.8
Income taxes paid	11.7	19.4	29.2	-18.1	4.36	17.2	23.6	13.1

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.35 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	90.8%	Gross profit / revenue.
Operating margin	9.5%	Operating income / revenue.
EBITDA margin	20.8%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	5.3%	Pre-tax income / revenue.
Net margin	2.1%	Net income / revenue.
FCF margin	25.1%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	25.7%	Cash from operations / revenue.
Effective tax rate	60.7%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	2.5%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	0.7%	Net income / average total assets.
Return on invested capital (ROIC)	7.1%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	14.9%	Research and development expense / revenue.
Stock-based pay / revenue	8.8%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.6%	Capital expenditures / revenue.
D&A / revenue	11.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	0.6%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	1.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	7.7%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-0.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	1.8%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	7.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	32.9%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	269.2%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA growth, 1y	27.6%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	45.6%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income growth, 1y	85.7%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	125.0%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	-8.7%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	4.6%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	5.0%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-10.0%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	4.8%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	8.2%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-15.0%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-8.9%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-2.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	1.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-4.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-0.9%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-9.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-4.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	5.4%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.38x	Current assets / current liabilities.
Quick ratio	0.41x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.26x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.75x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	20.8%	Total debt / total assets.
Liabilities / assets	72.4%	Total liabilities / total assets.
Net debt	$190.5M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	1.16x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	1.84x	Operating income / interest expense.
Working capital	$441.5M	Current assets - current liabilities.
Goodwill and intangibles / assets	20.9%	(Goodwill + intangible assets) / total assets.
Tangible book value	$159.0M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.34x	Revenue / average total assets.
Fixed asset turnover	68.2x	Revenue / average property, plant and equipment.
Receivables turnover	4.31x	Revenue / average receivables.
Days sales outstanding	85 days	365 x average receivables / revenue.
Days payables	45 days	365 x average accounts payable / cost of revenue.
FCF conversion	1,213.0%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	2.2%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.05	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$2.26	Revenue / diluted weighted shares.
FCF per share	$0.57	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.58	Cash from operations / diluted weighted shares.
Book value per share	$1.86	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$0.46	Tangible book value / shares outstanding.
Cash per share	$0.85	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	43.1%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$1.14B	Share price x shares outstanding.
Enterprise value	$1.33B	Market cap + total debt - cash - short-term investments.
P/E	70.3x	Market cap / net income. Only when net income is positive.
P/S	1.46x	Market cap / revenue.
P/B	1.76x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	7.19x	Market cap / tangible book value, when positive.
P/FCF	5.80x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.67x	Market cap / cash from operations, when positive.
EV/Sales	1.70x	Enterprise value / revenue.
EV/EBIT	17.8x	Enterprise value / operating income, when both are positive.
EV/EBITDA	8.15x	Enterprise value / EBITDA, when both are positive.
EV/FCF	6.76x	Enterprise value / free cash flow, when both are positive.
FCF yield	17.2%	Free cash flow / market cap.
Earnings yield	1.4%	Net income / market cap (the inverse of P/E).
Shareholder yield	7.4%	(Dividends paid + share buybacks) / market cap.

What was GoodRx Holdings, Inc.'s revenue in fiscal 2025?

GoodRx Holdings, Inc. reported revenue of $796.9M for fiscal 2025, 0.6% higher than the year before.

Was GoodRx Holdings, Inc. profitable in fiscal 2025?

Yes. Net income was $30.4M, a net margin of 3.8%.

How much free cash flow did GoodRx Holdings, Inc. generate in fiscal 2025?

Cash from operations of $167.9M minus capital expenditures of $3.5M left free cash flow of $164.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to GoodRx Holdings, Inc.